Edgewise Therapeutics (EWTX) Stock Forecast & Price Target

Edgewise Therapeutics is supported by a sharply improved balance sheet after the June 2026 Servier transaction delivered $1.55 billion upfront, with up to $2.65 billion total consideration and cash of $1.7 billion exiting 3Q26, reducing dilution risk and funding development into the early 2030s. Its core bull case centers on EDG-7500, which showed broad Phase 2 CIRRUS-HCM benefits in 53 patients and across more than 240 exposed individuals with over 700 echocardiograms, including no LVEF below 50%, plus meaningful gains in LVOT gradient, KCCQ, NT-proBNP, and diastolic function. That differentiated safety profile, together with potential echo-light or fixed-dose use and a Phase 3 start targeted for YE26, could expand HCM treatment beyond specialty centers and leave EDG-15400 and EDG-003 as additional upside.

Edgewise Therapeutics is exposed to meaningful regulatory and development risk, as its pipeline is still clinical-stage and regulators could require additional data, longer studies, REMS, or echo monitoring that would weaken the commercial case for EDG-7500 and delay approval. The thesis is further pressured by limited evidence, with EDG-7500 supported by only 53 patients treated for 12 weeks, while larger pivotal trials must still confirm efficacy, safety, and durability in a market already occupied by mavacamten and aficamten. Financially, the company may need additional external funding if the Servier transaction is delayed or fails to close, and higher Phase 3 costs, pipeline expansion, or business development could further strain liquidity and create dilution risk.